Indegene Limited Approves Qended June 30, 2026 Financial Results; Reports Segment Performance

Indegene Limited Approves Qended June 30, 2026 Financial Results; Reports Segment Performance​

Indegene Limited announced its unaudited Standalone and Consolidated Financial Results for the quarter ending June 30, 2026. The Board of Directors approved the results, along with the allotment under ESOP Scheme 2020.

The company reported a total income of 10,921 (t) million in the consolidated results for the quarter, up from 7,829 (t) million in the previous year's corresponding period. The unaudited Standalone Financial Results showed Total Income at 3,746 (t) million for the quarter ended June 30, 2026.

The results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on July 30, 2026.

Financial Highlights and Performance Summary​

Financial data for both Consolidated and Standalone operations is provided below, showing key metrics across the quarter ended June 30, 2026, and comparison periods:

Consolidated Unaudited Financial Results (Quarter ended June 30, 2026)


Standalone Unaudited Financial Results (Quarter ended June 30, 2026)

Segment and Operational Status​

The Group has two reportable segments: Enterprise Commercial Solutions and Enterprise Medical Solutions. Revenue data for these segments is summarized as follows:

Segment Revenue (in t millions)

IPO Fund Utilization and Dividends​

The utilization of the Initial Public Offer (IPO) proceeds is complete. The company had received an amount of 7,246 (t) million from the fresh issue, which was fully utilized by June 30, 2026. This usage included repayment or prepayment of indebtedness to a Material Subsidiary, funding capital expenditure requirements for Indegene Inc., technology and cybersecurity costs (350 t million), and general corporate purposes.

The Board of Directors proposed a final dividend of 2.25 per equity shares for the financial year ended March 31, 2026.

Key Financial Events​

Litigation Provision:
Regarding litigation expenses, specifically a class action lawsuit filed in the U.S. District Court of New Jersey related to the Telephone Consumer Protection Act (TCPA), the Group concluded that a present obligation exists and an outflow of economic resources was probable. Consequently, the Group recognized a provision of U03 (USO 2.30 million) for these expenses as an exceptional item in the results for the quarter and year ended March 31, 2026.

IPO Proceeds:
The utilization confirmed that all proceeds from the IPO have been allocated across the specified purposes up to June 30, 2026. The original objects of the IPO were revised in August 2025 to account for exchange rate fluctuations related to debt repayment and service cost classification.

Audit Affirmation:
The Chief Financial Officer, Suhas Prabhu, declared that the Statutory Auditors, Deloitte Haskins & Sells, submitted an unmodified opinion on the unaudited Financial Results for the quarter ended June 30, 2026.

INDGN Stock Price Movement​

Indegene Limited shares today shed 1.80% of their value, closing at ₹514.70 after trading session concluded. The equity saw a traded volume of 555,545 shares as it finished below its opening price of ₹519.6.